Trial Profile

First-in-human Phase 1 single ascending dose study assessing ART2612

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART26.12 (Primary)
Indications Chemotherapy-induced damage; Peripheral neuropathies
Focus Adverse reactions; First in man

Most Recent Events

15 Oct 2025 According to Artelo Biosciences media release, data from this study is going to be presented at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit, taking place October 15-16, 2025, in Boston, Massachusetts.
15 Oct 2025 Results presented in the Artelo Biosciences media release.
25 Aug 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com